EXPERIENCE OF USING NABUMETONE IN PATIENTS WITH REACTIVE ARTHRITIS

Protsenko G.O., Pasternak M.L.

• SI «NSC» Institute of Cardiology named after acad. M.D. Strazhesko» of the National Academy of Medical Sciences of Ukraine

Summary. The paper presents data from a clinical study of nonsteroidal anti-inflammatory drug (NSAID) nabumetone in patients with reactive arthritis. The doses and duration of its administration have been worked out, depending on the clinical and laboratory activity of reactive arthritis. For the first time, a group of patients with postcoid reactive arthritis was described and the expediency of using nabumetone in the complex treatment of such patients was substantiated. The effectiveness of this NSAID was assessed by the general condition of the patient, the dynamics of the articular and inflammatory indices, the number of affected joints, the volume of active and passive movements. Richie’s inflammatory index was analyzed in patients with ReA against the background of osteoarthritis. After 30 days of treatment in the group as a whole, the articular index decreased by 77%, the inflammatory index — by 78.5%, the Ricci index — 55.6%, which confirms the effectiveness of the symptomatic action of nabumeton. In patients with synovitis, according to joint ultrasound, effusion regression was observed. The tolerability of the drug nabumetone was satisfactory and did not cause any negative consequences both from the gastrointestinal tract and from the cardiovascular system, which makes it possible to include it in the complex therapy of reactive arthritis.